title: The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate.
abstract: Using Triton WR-1339-induced hyperlipidemic rats as an experimental model, we investigated whether compound 4 [N-(9,10-dihydro-9,10-dioxoanthracen-2-yl)benzofuran-2-carboxamide] and compound 5 [N-(4-benzoylphenyl)benzofuran-2-carboxamide], two novel anti-hyperlipidemic agents, have any effect on plasma triglyceride (TG), total cholesterol (TC), and high-density lipoprotein cholesterol levels (HDL-C) levels. The tested animals were divided into control (CG), hyperlipidemic (HG), and compounds 4, 5, and bezafibrate (BF) treated groups. At a dose of 15 mg/kg body weight, compounds 4, 5, and BF significantly reduced elevated plasma TG levels after 7 and 24 h. Furthermore, HDL-C levels were remarkably increased in all treated groups after 7 and 24 h compared to the hyperlipidemic control group. However, only compounds 4 and 5 treated groups clearly showed a significant reduction in plasma total cholesterol levels after 7 and 24 h. It is therefore reasonable to assume that compounds 4 and 5 may have promising potential in the treatment of hyperlipidemia and atherosclerosis.
authors.affiliation: Faculty of Pharmacy, Al-Zaytoonah Private University, Amman, Jordan. gassan10@yahoo.com
authors.forename: Ghassan
authors.initials: G
authors.lastname: Shattat
authors.forename: Tariq
authors.initials: T
authors.lastname: Al-Qirim
authors.forename: Kamal
authors.initials: K
authors.lastname: Sweidan
authors.forename: Moyad
authors.initials: M
authors.lastname: Shahwan
authors.forename: Waseem
authors.initials: W
authors.lastname: El-Huneidi
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Al-Hiari
mesh_terms: D000818:Animals; D000873:Anthracenes / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D050197:Atherosclerosis / Q000517:prevention & control; D001572:Benzofurans / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use*; D001629:Bezafibrate / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003902:Detergents / Q000633:toxicity; D015195:Drug Design; D006949:Hyperlipidemias / Q000097:blood* / Q000139:chemically induced / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D015394:Molecular Structure; D011092:Polyethylene Glycols / Q000633:toxicity; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000873:Anthracenes; D001572:Benzofurans; D008076:Cholesterol, HDL; D003902:Detergents; D000960:Hypolipidemic Agents; D008055:Lipids; C556598:N-(4-benzoylphenyl)benzofuran-2-carboxamide; C556597:N-(9,10-dihydro-9,10-dioxoanthracen-2-yl)benzofuran-2-carboxamide; D014280:Triglycerides; D011092:Polyethylene Glycols; D002784:Cholesterol; C016811:tyloxapol; D001629:Bezafibrate